Demographics and Clinical Characteristics of Patient Population
| Characteristic . | Total (n = 1906) . | Preintervention Period (n = 959) . | Intervention Period (n = 947) . | P . |
|---|---|---|---|---|
| Age, y, median (IQR) | 6.0 (3.1–9.8) | 6.4 (3.3–10.1) | 5.5 (2.9–9.6) | .003 |
| Male sex, n (%) | 997 (52.4) | 500 (52.1) | 497 (52.7) | .80 |
| Fever, n (%) | 1242 (65.2) | 645 (67.3) | 597 (63.0) | .05 |
| Hypoxia, n (%) | ||||
| Pulse oxygen not performed | 1155 (60.7) | 918 (95.7) | 237 (25.1) | <.001 |
| Normal oxygen saturation, ≥92% | 729 (38.3) | 38 (4.0) | 691 (73.2) | .08 |
| Abnormal oxygen saturation or hypoxic, <92% | 19 (1.0) | 3 (0.3) | 16 (1.7) | |
| Asthma, n (%) | 324 (17.0) | 151 (15.7) | 173 (18.3) | .14 |
| Wheezing, n (%) | 373 (19.6) | 173 (18.1) | 200 (21.2) | .09 |
| Immunizations up to date, n (%) | 1734 (91.0) | 869 (90.6) | 865 (91.3) | .04 |
| Receipt of influenza vaccination, n (%) | 1048 (55.0) | 512 (53.4) | 536 (56.6) | <.001 |
| Medication allergy, n (%) | 222 (13.8) | 88 (13.1) | 134 (14.2) | .52 |
| Penicillin | 163 (11.6) | 59 (9.2) | 104 (11.0) | <.001 |
| Macrolide | 10 (0.5) | 5 (0.5) | 5 (0.5) | .98 |
| Cephalosporin | 39 (2.0) | 21 (2.2) | 18 (1.9) | .66 |
| Vancomycin | 2 (0.1) | 1 (0.1) | 1 (0.1) | .99 |
| Penicillin and cephalosporin | 9 (0.5) | 6 (0.6) | 3 (0.3) | .33 |
| Penicillin and macrolide | 1 (0.1) | 0 (0.0) | 1 (0.1) | .31 |
| Characteristic . | Total (n = 1906) . | Preintervention Period (n = 959) . | Intervention Period (n = 947) . | P . |
|---|---|---|---|---|
| Age, y, median (IQR) | 6.0 (3.1–9.8) | 6.4 (3.3–10.1) | 5.5 (2.9–9.6) | .003 |
| Male sex, n (%) | 997 (52.4) | 500 (52.1) | 497 (52.7) | .80 |
| Fever, n (%) | 1242 (65.2) | 645 (67.3) | 597 (63.0) | .05 |
| Hypoxia, n (%) | ||||
| Pulse oxygen not performed | 1155 (60.7) | 918 (95.7) | 237 (25.1) | <.001 |
| Normal oxygen saturation, ≥92% | 729 (38.3) | 38 (4.0) | 691 (73.2) | .08 |
| Abnormal oxygen saturation or hypoxic, <92% | 19 (1.0) | 3 (0.3) | 16 (1.7) | |
| Asthma, n (%) | 324 (17.0) | 151 (15.7) | 173 (18.3) | .14 |
| Wheezing, n (%) | 373 (19.6) | 173 (18.1) | 200 (21.2) | .09 |
| Immunizations up to date, n (%) | 1734 (91.0) | 869 (90.6) | 865 (91.3) | .04 |
| Receipt of influenza vaccination, n (%) | 1048 (55.0) | 512 (53.4) | 536 (56.6) | <.001 |
| Medication allergy, n (%) | 222 (13.8) | 88 (13.1) | 134 (14.2) | .52 |
| Penicillin | 163 (11.6) | 59 (9.2) | 104 (11.0) | <.001 |
| Macrolide | 10 (0.5) | 5 (0.5) | 5 (0.5) | .98 |
| Cephalosporin | 39 (2.0) | 21 (2.2) | 18 (1.9) | .66 |
| Vancomycin | 2 (0.1) | 1 (0.1) | 1 (0.1) | .99 |
| Penicillin and cephalosporin | 9 (0.5) | 6 (0.6) | 3 (0.3) | .33 |
| Penicillin and macrolide | 1 (0.1) | 0 (0.0) | 1 (0.1) | .31 |
IQR, interquartile range.